| JaLCDOI | 10.18926/AMO/47013 |
|---|---|
| フルテキストURL | 65_5_315.pdf |
| 著者 | Wang, Lei| Kaku, Haruki| Huang, Peng| Xu, Kexin| Yang, Kai| Zhang, Jiheng| Li, Ming| Xie, Liping| Wang, Xiaofeng| Sakai, Akiko| Watanabe, Masami| Nasu, Yasutomo| Shimizu, Kenji| Kumon, Hiromi| Na, Yanqun| |
| 抄録 | Deficiencies in the human DNA repair gene WRN are the cause of Werner syndrome, a rare autosomal recessive disorder characterized by premature aging and a predisposition to cancer. This study evaluated the association of WRN Leu1074Phe (rs1801195), a common missense single nucleotide polymorphism in WRN, with prostate cancer susceptibility in Chinese subjects. One hundred and forty-seven prostate cancer patients and 111 male cancer-free control subjects from 3 university hospitals in China were included. Blood samples were obtained from each subject, and the single nucleotide polymorphism WRN Leu1074Phe was genotyped by using a Snapshot assay. The results showed that WRN Leu1074Phe was associated with the risk of prostate cancer in Chinese men and that the TG/GG genotype displayed a decreased prevalence of prostate cancer compared with the TT genotype (OR＝0.58, 95%CI:0.35-0.97, p＝0.039). Through stratified analysis, more significant associations were revealed for the TG/GG genotype in the subgroup with diagnosis age <_ 72 yr (OR＝0.27, 95%CI:0.12-0.61, p＝0.002) and in patients with localized diseases (OR＝0.36, 95%CI:0.19-0.70, p＝0.003). However, no statistically significant difference was found in the subgroup with age ＞72 yr or in patients with advanced diseases. We concluded that the genetic variant Leu1074Phe in the DNA repair gene WRN might play a role in the risk of prostate cancer in Chinese subjects. |
| キーワード | polymorphism prostatic neoplasms single nucleotide susceptibility WRN |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2011-10 |
| 巻 | 65巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 315 |
| 終了ページ | 323 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2011 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22037267 |
| Web of Science KeyUT | 000296116400005 |
| JaLCDOI | 10.18926/AMO/48076 |
|---|---|
| フルテキストURL | 66_1_7.pdf |
| 著者 | Kawauchi, Keiichiro| Watanabe, Masami| Kaku, Haruki| Huang, Peng| Sasaki, Kasumi| Sakaguchi, Masakiyo| Ochiai, Kazuhiko| Huh, Nam-ho| Nasu, Yasutomo| Kumon, Hiromi| |
| 抄録 | The preclinical safety and therapeutic efficacy of adenoviral vectors that express the REIC/Dkk-3 tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy. The Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer effects in vitro and in vivo, and we herein report the results of two in vivo studies. First, intra-tumor Ad-hREIC administration was examined for toxicity and therapeutic effects in a subcutaneous tumor model using the PC3 prostate cancer cell line. Second, intra-prostatic Ad-mREIC administration was tested for toxicity in normal mice. The whole-body and spleen weights, hematological and serum chemistry parameters, and histological evaluation of tissues from throughout the body were analyzed. Both experiments indicated that there was no significant difference in the examined parameters between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group. In the in vitro analysis using PC3 cells, a significant apoptotic effect was observed after Ad-hREIC treatment. Confirming this observation, the robust anti-tumor efficacy of Ad-hREIC was demonstrated in the in vivo subcutaneous prostate cancer model. Based on the results of these preclinical experiments, we consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clinical treatment of prostate cancer. |
| キーワード | REIC Dickkopf-3 gene therapy prostate cancer preclinical study |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-02 |
| 巻 | 66巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 7 |
| 終了ページ | 16 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22358134 |
| Web of Science KeyUT | 000300800700002 |
| JaLCDOI | 10.18926/AMO/48078 |
|---|---|
| フルテキストURL | 66_1_23.pdf |
| 著者 | Watanabe, Toyohiko| Inoue, Miyabi| Ishii, Ayano| Yamato, Toyoko| Yamamoto, Masumi| Sasaki, Katsumi| Kobayashi, Yasuyuki| Araki, Motoo| Uehara, Shinya| Saika, Takashi| Kumon, Hiromi| |
| 抄録 | Polypropylene mesh implants for the correction of pelvic organ prolapse (POP) are now available in Japan. We developed an innovative approach for correcting POP by placing polypropylene mesh transvaginally with laparoscopic assistance. From June 2007 through March 2010, sixteen consecutive patients with symptomatic stage 2 or 3 pelvic organ prolapse underwent the laparoscopic-assisted tension-free vaginal mesh procedure at Okayama University Hospital. All patients were evaluated before and at 1, 3, 6, and 12 months after surgery. Female sexual function was also evaluated with the Female Sexual Function Index (FSFI). The procedure was performed successfully without significant complications. Fifteen of 16 patients were considered anatomically cured (93.8%) at 12 months postoperatively. One patient with a recurrent stage 3 vaginal vault prolapse required sacral colpopexy six months postoperatively. Total FSFI scores improved significantly from 10.3±1.3 at baseline to 18.0±1.2 at 12 months after surgery. The laparoscopic-assisted trans-vaginal mesh is a safe, effective, and simple procedure for POP repairs. The procedure not only restores anatomic relationships but also improves sexual function. |
| キーワード | tension-free vaginal mesh pelvic organ prolapse laparoscopic female urology sexual function |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2012-02 |
| 巻 | 66巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 23 |
| 終了ページ | 29 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2012 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 22358136 |
| Web of Science KeyUT | 000300800700004 |
| フルテキストURL | fulltext20230421-01.pdf figure20230421-01.pdf |
|---|---|
| 著者 | Nakasuka, Takamasa| Ohashi, Kadoaki| Nishii, Kazuya| Hirabae, Atsuko| Okawa, Sachi| Tomonobu, Nahoko| Takada, Kenji| Ando, Chihiro| Watanabe, Hiromi| Makimoto, Go| Ninomiya, Kiichiro| Fujii, Masanori| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Kumon, Hiromi| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| キーワード | EGFR mutation Non-small cell lung cancer Antitumor immunity Non-inflamed tumor Ad-SGE-REIC Gene therapy PD-1 |
| 備考 | ©2023 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 License. http://creativecommons.org/licenses/by-nc-nd/4.0/. This is the accepted manuscript version. The formal published version is available at https://doi.org/10.1016/j.lungcan.2023.01.018.| This fulltext file will be available in Apr. 2024.| |
| 発行日 | 2023-04 |
| 出版物タイトル | Lung Cancer |
| 巻 | 178巻 |
| 出版者 | Elsevier BV |
| 開始ページ | 1 |
| 終了ページ | 10 |
| ISSN | 0169-5002 |
| NCID | AA10785743 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2023 Elsevier B.V. |
| 論文のバージョン | author |
| PubMed ID | 36753780 |
| DOI | 10.1016/j.lungcan.2023.01.018 |
| Web of Science KeyUT | 000931976300001 |
| 関連URL | isVersionOf https://doi.org/10.1016/j.lungcan.2023.01.018 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Gohara, Yuma| Tomonobu, Nahoko| Kinoshita, Rie| Futami, Junichiro| Audebert, Léna| Chen, Youyi| Komalasari, Ni Luh Gede Yoni| Jiang, Fan| Yoshizawa, Chikako| Murata, Hitoshi| Yamamoto, Ken-ichi| Watanabe, Masami| Kumon, Hiromi| Sakaguchi, Masakiyo| |
| キーワード | Breast cancer REIC/Dkk-3 PD-L1 Immune checkpoint Cancer therapy |
| 備考 | The version of record of this article, first published in Journal of Molecular Medicine, is available online at Publisher’s website: http://dx.doi.org/10.1007/s00109-023-02292-w| |
| 発行日 | 2023-03-04 |
| 出版物タイトル | Journal of Molecular Medicine |
| 巻 | 101巻 |
| 号 | 4号 |
| 出版者 | Springer Science and Business Media LLC |
| 開始ページ | 431 |
| 終了ページ | 447 |
| ISSN | 0946-2716 |
| NCID | AA11034065 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s) 2023 |
| 論文のバージョン | publisher |
| PubMed ID | 36869893 |
| DOI | 10.1007/s00109-023-02292-w |
| Web of Science KeyUT | 000943221900001 |
| 関連URL | isVersionOf https://doi.org/10.1007/s00109-023-02292-w |